Home Compare LLY vs ROG.SW
Stock Comparison · Industry comparison · Drug Manufacturers - General

Eli Lilly and Company vs Roche Holding: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Eli Lilly and Company carrying a narrow edge on growth. Roche still leads on valuation and stability, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in growth, but profitability adds another real layer to the result.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. LLY and ROG.SW share the same industry classification.

For a similarity-based comparison, see how Eli Lilly and Company and Roche each position within their functional peer groups in AssetNext.

Peer-Relative Score
LLY
Eli Lilly and Company
68
Peer-Score
Signal qualityHigh
vs
ROG.SW
Roche Holding AG
63
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: LLY vs ROG.SW Profitability 100 75 Stability 34 51 Valuation 44 64 Growth 88 55 LLY ROG.SW
Gap Ranking
#1 Growth +33
#2 Profitability +25
#3 Valuation +20
#4 Stability +17
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for LLY and ROG.SW Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer LLYROG.SW Relative valuation Structural strength

Eli Lilly and Company looks stronger, but the price setup still looks more supportive for Roche Holding AG.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Both rank well on growth, but Eli Lilly and Company still holds a clear edge.
Profitability
On profitability, the edge still sits with Eli Lilly and Company, even though both profiles look solid.
Growth — Dominant Gap
LLY
88
ROG.SW
55
Gap+33in favour of LLY

One company is still expanding while the other is contracting, which creates a very wide growth split.

What keeps the gap from being one-sided

Absolute pricing still looks more supportive for Roche, with a forward P/E that is 7 turns lower there.

What this means for the comparison

The lead is built on both growth and profitability — though valuation still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the LLY vs ROG.SW comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how LLY and ROG.SW each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.